JP Morgan Initiates Coverage On Seaport Therapeutics with Overweight Rating, Announces Price Target of $42

Seaport Therapeutics

Seaport Therapeutics

SPTX

0.00

JP Morgan analyst Tessa Romero initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Overweight rating and announces Price Target of $42.